Medicine guide

Provenge

Active substance: Autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor (sipuleucel-T)
Used in: Cancer treatments and immune-system medicines
Made by: Dendreon UK Ltd
Source: Official label

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Provenge is indicated for treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate-resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated.

From the official label · 2026-09-30 · European Medicines Agency

Made by	Dendreon UK Ltd
Active substance	Autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor (sipuleucel-T)
Used in	Cancer treatments and immune-system medicines
Classification	L03AX17 · Cancer treatments and immune-system medicines
Additional monitoring ▼	Yes — under additional monitoring (black triangle). Report suspected side effects.
Authorised on	2013-09-06
Last updated by the regulator	2015-05-19
EMA product number	EMEA/H/C/002513

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).